Advancements in Diagnostics
Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…
Posted by
Safeguard Insights
Strong Diversification Strategy Can Thwart Grim VC Numbers
The data from Thomson Reuters/NVCA on venture capital investing over the past 10 years has sparked an onslaught of debate and media coverage highlighting the…
Posted by
Analyst Coverage Update
Today, ROTH Capital Partners initiated coverage on SFE with a BUY Rating and a 12-Month Target Price of $16.50 Per Share. Safeguard Scientifics’ (NYSE: SFE)…
Posted by
The Current Competitive M&A Climate
As reported recently in The Wall Street Journal, companies are sitting on nearly $2 trillion of cash. As a result, shareholders are beginning to ask…
Posted by
Safeguard CEO featured on TheStreet.com
Last week, Safeguard Scientifics’ President and CEO Peter J. Boni sat down with Gregg Greenberg of TheStreet.com to discuss the emergence of IPO candidates from…
Posted by
IPOs: A Financing Event
On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…
Posted by
Q2 2010 Results Transcript, Podcast, Slides Now Available
For those of you who were unable to participate in our second quarter results conference call yesterday, you can now download the complete transcript, podcast,…
Posted by
Safeguard Scientifics’ Aggregate Partner Company Revenue Up 47 Percent; Increases 2010 Guidance to be Between $325 Million and $350 Million
This morning, we announced that aggregate partner company revenue for the three months ended June 30, 2010 was $91.6 million, up 47 percent from $62.3…
Posted by
Reminder: Safeguard Scientifics’ Quarterly Results Call Tomorrow Morning
REMINDER: Second quarter results to be issued tomorrow. Here’s the link: www.safeguard.com/results
Posted by
